Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prialt Review Shows Swing In FDA’s Statistical Preference

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA reanalyzed Elan's Prialt (ziconotide) data using its now-preferred conservative technique for imputation of missing data in chronic pain trials to assuage concerns that the protocol-specified analysis could magnify treatment effect

You may also be interested in...



FDA Advice On Missing Data May Be To Avoid Missing It In The First Place

FDA officials respond to the recommendations of a National Research Council Panel on handling missing data in clinical trials, giving early indications of how FDA could be viewing a forthcoming guidance on the issue.

Missing Clinical Trial Data: "Mixed Model" Approach Gains Ground At FDA

Clinical trial sponsors should adopt a mixed statistical model to cope with missing data rather than relying on the "last observation carried forward" model that was formerly perceived as regulators' favorite

Statistics Bedeviled But Did Not Derail Cymbalta Fibromyalgia Approval

Lilly ran into one review issue with its fibromyalgia NDA for Cymbalta (duloxetine) because it did not adhere to a "well established policy" of the FDA division responsible for analgesic drugs regarding imputation of missing data, a recurring statistical issue in pain drug reviews, review documents show

Related Content

Topics

UsernamePublicRestriction

Register

PS003084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel